Table 3.
Clinical Characteristic as a Function of Serum Endostatin
| ESLow (n = 50) | ESHigh (n = 32) | P Value | |
|---|---|---|---|
| Demographics | |||
| Age, mean ± SD, yr | 58.5 ± 11.9 | 61.1 ± 15.4 | 0.3 |
| Female, n (%) | 41 (82) | 27 (84) | 1.0 |
| Race, EA/AA/other (EA%) | 40/7/3 (80) | 26/6/0 (81) | 0.1 |
| 6 MWD, mean (range), m | 411 (228–671) | 331 (211–550) | <0.0001 |
| NYHA-FC, n (%) | |||
| I | 10 (20) | 0 (0) | 0.0003 |
| II | 27 (54) | 10 (31.3) | |
| III | 13 (26) | 17 (53.1) | |
| IV | 0 (0) | 4 (12.5) | |
| Laboratory chemistries, mean (range) | |||
| Serum sodium | 140 (135–147) | 138 (23–144) | 0.06 |
| Serum creatinine | 0.9 (0.4–2.1) | 1.2 (0.6–2.5) | 0.0007 |
| NT-proBNP, pg/ml | 1,045 (20–6,922) | 3,362 (94–11,698) | 0.003 |
| PAH-specific therapy, n (%) | |||
| PDE5 inhibitor | 30 (60.0) | 22(68.8) | 0.4 |
| ETRA | 23 (46.0) | 16 (50.0) | 0.9 |
| Prostacyclin | 11 (12.5) | 4 (18.3) | 0.6 |
| Ca-channel blockers | 5 (10.0) | 0 (0.0) | 0.2 |
| Treatment naive | 6 (12.0) | 7 (21.9) | 0.4 |
| Hemodynamic, mean ± SD | |||
| RAP, mm Hg | 8 ± 5 | 8 ± 5 | 0.9 |
| mPAP, mm Hg | 41 ± 13 | 46 ± 16 | 0.1 |
| PCWP, mm Hg | 10 ± 4 | 12 ± 4 | 0.3 |
| PVR, Wood units | 8.7 ± 5.9 | 10.5 ± 6.9 | 0.2 |
| CO, L/min | 5.0 ± 1.7 | 4.5 ± 1.4 | 0.2 |
| Cardiac index, L/min/m2 | 2.7 ± 0.8 | 2.4 ± 0.6 | 0.1 |
Definition of abbreviations: 6 MWD = 6-minute-walk distance; AA = African American; Ca = calcium; CO = cardiac output; EA = European American; ESHigh = endostatin ≥ 66 ng/ml; ESlow = endostatin < 66 ng/ml; ETRA = endothelin receptor antagonist; mPAP = mean pulmonary artery pressure; NT-proBNP = N-terminal pro-brain natriuretic peptide; NYHA-FC = New York Heart Association functional class; PAH = pulmonary arterial hypertension; PCWP = pulmonary capillary wedge pressure; PDE5 = phosphodiesterase type five; PVR = pulmonary vascular resistance; RAP = right atrial pressure.